Viscosupplementation market seen reaching $5.2 billion by 2033

Persistence Market Research says the global viscosupplementation market will grow from $3.4 billion in 2026 to $5.2 billion by 2033, driven by osteoarthritis cases, aging populations and demand for non-surgical joint care. Hospitals lead the market now, while North America remains the top region.

Why it matters: - Viscosupplementation is gaining traction as a non-surgical option for osteoarthritis and other joint disorders. - Rising demand for minimally invasive orthopedic care is helping patients delay joint replacement surgery and maintain mobility. - The growth outlook signals more opportunity for hyaluronic acid injection makers, orthopedic providers and hospital systems.

What happened: - Persistence Market Research projects the global viscosupplementation market will rise from US$3.4 billion in 2026 to US$5.2 billion by 2033. - The forecast implies a 6.2% compound annual growth rate from 2026 to 2033. - The report was released July 15, 2026. - The market includes therapies that inject hyaluronic acid into affected joints to reduce pain, improve lubrication and restore mobility. - Hospitals are the leading end users. - North America is the leading regional market.

The details: - Growing osteoarthritis prevalence, continuous product innovation, expanding orthopedic care facilities and higher patient awareness are supporting demand. - Single-injection and multiple-injection therapies are both widely available. - Single-injection products are becoming more popular because they can improve convenience, reduce hospital visits and support patient compliance. - Hospitals hold the largest share because they offer experienced orthopedic specialists, advanced diagnostic technologies and comprehensive care. - Orthopedic clinics are seeing more patient visits as awareness of joint-preservation therapies rises. - North America leads because of advanced healthcare infrastructure, higher healthcare spending, favorable reimbursement policies and stronger adoption of advanced orthopedic therapies. - Europe remains a significant market because of an aging population and demand for non-invasive orthopedic treatments. - Asia Pacific is expected to grow at a healthy pace as healthcare infrastructure expands, patient awareness improves and orthopedic investment rises. - The report says market growth is supported by increasing awareness of minimally invasive orthopedic procedures and a rapidly aging population. - Healthcare providers are increasingly recommending viscosupplementation to delay joint replacement surgeries and improve quality of life. - The report also points to continuous improvements in hyaluronic acid formulations and stronger physician confidence in viscosupplementation.

Between the lines: - The market is benefiting from a broader shift toward treatment plans that manage pain earlier and avoid surgery when possible. - Reimbursement gaps, uneven awareness in developing regions and variable treatment outcomes remain barriers to wider adoption. - Competition from medications, physical therapy and surgery could limit use in some care settings. - Repeated injections can raise total treatment costs for some patients. - The report's growth case suggests manufacturers that improve durability, comfort and convenience may have an edge.

What's next: - Market participants are likely to keep investing in orthopedic research and improved injectable therapies. - Emerging economies could add demand as healthcare access and early osteoarthritis awareness improve. - Continued product innovation and physician education are likely to shape adoption through 2033. - The report identifies Sanofi, Ferring Pharmaceuticals, Seikagaku Corporation, Bioventus LLC, Anika Therapeutics, Fidia Farmaceutici, Chugai Pharmaceutical, Zimmer Biomet, Lifecore Biomedical and LG Chem as key players. - More information is available in the report sample, customization request and full report purchase page.

The bottom line: - Viscosupplementation is moving from a niche orthopedic option toward a broader growth market, with aging populations and preference for non-surgical care doing the heavy lifting.